The criterion standard treatment for mid and distal locally advanced rectal cancer is total mesorectal excision (TME).
1 Evidence supports the addition of neoadjuvant therapy (NAT) in selected cases, which include extramural venous invasion (EMVI), threatened circumferential resection margin (CRM), cancer stages cT3 to T4, or node-positive tumors. The main objective of NAT is to reduce tumor burden and facilitate downstaging, increasing the possibility of achieving higher rates of R0 (ie, surgical margin microscopically negative for residual tumor) resections.
2,3 Patients with good response to NAT may benefit from sphincter-saving procedures or even an active surveillance strategy (watch and wait), thus avoiding surgical comorbidities.
4-7